姜乃榕 助研究員－論文

PUBLICATIONS: (since 2015)
  1. Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules. 13;11(1):97, 2021.
  2. Shiah HS*, Chiang NJ*, Lin CC, Yen CJ, Tsai HJ, Wu SY, Su WC, Chang KY, Wang CC, Chang JY, Chen LT. Phase I dose escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors. The Oncologist. doi:10.1002/onco.13612, 2020. Online ahead of print. (*Co-first author)
  3. Gopinathan P*, Chiang NJ*, Wang CH, Sinha A, Tsai YC, Tu HC, Hung SC; Hsu PH, Shan YS, Lee GB. Aptamer probed isolation of circulating tumor cells in cholangiocarcinoma patients. Sensors and Actuators B: Chemical. 2020 Nov 1; 322: Article number 128569. (*Co-first author)
  4. Chiang NJ, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS, Shan YS, Chen LT. Multicentre, Phase II Study of Gemcitabine and S-1 in Patients With Advanced Biliary Tract Cancer: TG1308 Study. Liver Int. 40(10):2535-2543, 2020.
  5. Chiang NJ, Tsai KK, Chen JS, Yang SH, Hsiao HH, Shan YS, Chen LT. A Multicenter, Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine in Metastatic Pancreatic Adenocarcinoma -TCOG T1211 Study. European Journal of Cancer. 124: 123-130, 2020
  6. Gopinathan P*, Chiang NJ*, Bandaru A, Sinha A, Huang WY, Hung SC, Shan YS, Lee GB. Exploring Circulating Tumor Cells in Cholangiocarcinoma Using a Novel Glycosaminoglycan Probe on a Microfluidic Platform. Adv Healthc Mater. 9(10):e1901875, doi: 10.1002/adhm.201901875, 2020. (*Co-first author)
  7. Su YY*, Chiang NJ*, Tsai HJ, Yen CJ, Shan YS, Chen LT. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Sci Rep 10(1):7420, 2020. (*Co-first author)
  8. Kuo HY*, Chiang NJ*, Chuang CH, Chen CY, Wu IC, Chang TT, Tsai HM, Lin YC. Impact of Immune Checkpoint Inhibitors With or Without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma. Oncology Research and Treatment. 1-10, 2020. (*Co-first author)
  9. Lin FC, Chang WL, Chiang NJ, Lin MY, Chung TJ, Pao TH, Lai WW, Tseng YL, Yen YT, Sheu BS. Radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy. PLoS One, 15(8):e0237114, 2020.
  10. Pao TH, Chang WL, Chiang NJ, Lin CY, Lai WW, Tseng YL, Lin FC. Pericardial Effusion After Definitive Concurrent Chemotherapy and Intensity Modulated Radiotherapy for Esophageal Cancer. Radiation Oncology. 15(1), 48, 2020.
  11. Hung LY*, Chiang NJ*, Tsai WC, Fu CY, Wang YC, Shan YS, Lee GB. A microfluidic chip for detecting cholangiocarcinoma cells in human bile. Sci Rep. 7(1):4248, 2017. (*Co-first author)
  12. Gopinathan P, Hung LY, Wang CH, Chiang NJ, Wang YC, Shan YS, Lee GB. Automated selection of aptamers againt cholangiocarcinoma cells on an integrated microfluidic platform. Biomicrofluidics. 11(4):044101, 2017.
  13. Chiang NJ, Chao TY, Hsieh RK, Wang CH, Wang YW, Yeh CG, Chen LT. A Phase I Dose–Escalation Study of PEP02 (Irinotecan Liposome Injection) in Combination with 5-Fluorouracil and Leucovorin in Advanced Solid Tumors. BMC Cancer, 16(1):907, 2016.
  14. Chiang NJ, Hsu C, Chen JS, Tsou HH, Shen YY, Chao Y, Chen MH, Yeh TS, Shan YS, Huang SF, Chen LT. Expression level of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Sci Rep. 3(6):25369. doi: 10.1038/srep25369, 2016.
  15. Chiang NJ, Chang JY, Shan YS, Chen LT. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. Expert Opin Pharmacother. 17(10):1413-20, 2016 (Review).
  16. Chiang NJ, Shan YS, Hung WC, Chen LT. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma. Int J Biochem Cell Biol. 67:110-114, 2015 (Review).
  17. SU YY, Chiang NJ, Wu CC, Chen, LT. Primary gastrointestinal stromal tumor of the liver in an anorectal melanoma survivor: a case report. Onco Lett. 10(4):2366-2370, 2015.
  18. Chiang NJ, Wu SN, Chen LT. The potent activation of Ca2+-activated K+ current by NVP-AUY922 in the human pancreatic duct cell line (PNAC-1) possibly independent of heat shock protein 90 inhibition. J Pharmacol Sci. 127(4): 404-13, 2015.
  19. Chen JS*, Hsu C*, Chiang NJ*, Tsai CS*, Tsou HH, Huang SF, Bai LY, Chang IC, Shiah HS, Ho CL, Yen CJ, Lee KD, Chiu CF, Rau KM, Yu MS, Yang Youngsen, Hsieh RK, Shan YS, Chao Y, Chen LT, on behalf of the Taiwan Cooperative Oncology Group. The final results of a KRAS mutation status-stratified, randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Annals of oncology. 26(5): 943-9, 2015. (*Co-first author)

ABSTRACTS

  1. NJ Chiang, CP Li, YW Wang, YY Su, YS Shan, LT Chen. The Association Between UGT1A1 Polymorphisms and Treatment Toxicities from Liposomal Irinotecan (Nal-IRI; Onivyde). JSMO, Kyoto, JAPAN, 18-20 July, 2019 (Travel grand award)
  2. NJ Chiang, MH Chen, MH Tsai, HW Tsai, LT Chen YS Shan. Mutation landscape and immune profile of EBV-associated lymphoepithelioma-like cholangiocarcinoma. ASCO GI,  2019.
  3. NJ Chiang, JS Chen, MH Chen, C Hsu, SH Yang, CJ Yen, YS Shan, LT Chen. Phase II Trial of Biweekly S-1 and Gemcitabine as the First-line Treatment in Patients with Locally Advanced and Metastatic Biliary Tract Cancer (TG1308 Study). ESMO Asia, 2018
  4. NJ Chiang, KK. Tsai, JS Chen, SH Yang, HH Hsiao, YS Shan, LT Chen. Multicenter, Phase II Trial of Biweekly S-1, Leucovorin (LV), Oxaliplatin and Gemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma (mPDAC): Final Report of TCOG T1211 Study. ESMO, 2018
  5. NJ Chiang, HS Shiah, CC Lin, CJ Yen, HJ Tsai, SY Wu, WC Su, KY Chang, LT Chen. A Phase I Dose Escalation Study of SCB01A, a Micro-tubular Inhibitor with Vascular Disrupting Activity in Patients Advanced Solid Tumors Refractory to Standard Therapy. ASCO,  June, 2017
  6. NJ Chiang, JS Chen, MH Chen, SH Yang, C Hsu, CJ Yen, HH Tsou, YS Shan, Li-Tzong Chen. A Phase II Trial of modified Gemcitabine plus S-1 combination as the First- line Treatment in Patients with Advanced Biliary Tract Cancer. TJCC, Taiwan, 6-7 May, 2017 
  7. NJ Chiang, KK Tsai, JS Chen, SH Yang, C Hsu, YS Shan, LT Chen. Multicenter, Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (the SLOG regimen) in Metastatic Pancreatic Adenocarcinoma (mPDAC)-TCOG T1211 Study. TJCC, Taiwan,  2016
  8. NJ Chiang, KH Yeh, CF Chiu, JS Chen, CC Yen,KD Lee, YL Lin, LY Bai, MH Chen, TH Lin, Y Yang, KM Rau, HH Hsiao, YS Shan, LT Chen. Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) failed to imatinib and sunitinib therapy. ASCO GI 2016.
Share Button

Comments are closed.